Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InsuletPODD -2.05%81 3-Year EBITDA Growth Rate is 63.40% as of Jun. 2026, which is 72% above its 10-year median of 36.80. GuruFocus rates PODD with a GF Score™ of 81/100 and a GF Value™ of $389.17 (Significantly Undervalued). Among 690 Medical Devices & Instruments companies, Insulet ranks better than 92.46% on this metric.
During the past 12 months, Insulet's average EBITDA Per Share Growth Rate was 67.50% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 63.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 37.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Insulet was 262.50% per year. The lowest was -15.90% per year. And the median was 36.80% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Insulet 3-Year EBITDA Growth Rate Related Terms
PODD vs GMED, PEN, BRKR: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Insulet's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insulet 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Insulet's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Insulet's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 63.40% mean?
Insulet (PODD) has a 3-Year EBITDA Growth Rate of 63.40% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Insulet and its competitors. This is 72% above median its historical median of 36.80. According to the industry distribution chart, Insulet ranks #52 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 7.5%.
Is Insulet's 3-Year EBITDA Growth Rate too high?
Insulet's current 3-Year EBITDA Growth Rate of 63.40% is 72% above median its 10-year median of 36.80. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.20. Insulet's value of 63.40% is 673.2% above this industry median. Based on the distribution chart, Insulet ranks #52 out of 690 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Insulet has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Insulet's 3-Year EBITDA Growth Rate compare to GMED and PEN?
According to the Medical Devices & Instruments industry distribution chart, Insulet ranks #52 out of 690 companies for 3-Year EBITDA Growth Rate. This places Insulet in the top 8% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.20. Insulet's value of 63.40% is 673.2% above this benchmark. While the company's 10-year median is 36.80 vs. the industry median of 8.20, Insulet has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Insulet's current 3-Year EBITDA Growth Rate of 63.40% is 673.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Insulet and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Insulet's current 3-Year EBITDA Growth Rate is 63.40%, which is 72% above median its own 10-year median of 36.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insulet stock overvalued right now?
Based on GuruFocus' analysis, Insulet (PODD) is currently considered Significantly Undervalued. The stock's GF Value™ is $389.17, compared to a current price of $143.34 — trading 63.2% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 63.40%, which is 72% above median its 10-year median of 36.80 and 673.2% above the Medical Devices & Instruments industry median of 8.20. Insulet's overall GF Score™ is 81/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Insulet (PODD), the current 3-Year EBITDA Growth Rate is 63.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insulet (PODD) Overvalued in 2026?
Based on GuruFocus' analysis, Insulet stock appears to be undervalued.
The current stock price of $143.34 is trading 63.2% below its estimated GF Value™ of $389.17.
GuruFocus considers Insulet to be Significantly Undervalued.
Key valuation signals for PODD:
3-Year EBITDA Growth Rate: 63.40% (72% above median its 10-year median of 36.80)
GF Value™: $389.17 vs. price of $143.34 (63.2% below fair value)
Industry Position: 673.2% above the Medical Devices & Instruments median (#52 of 690)
No single metric tells the full story. See the PODD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
81GF Score
Get the complete analysis for PODD
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PODD has been successfully added to your 
